US President Donald Trump has unveiled a new tariff policy targeting imported generic medicines, introducing a phased duty structure that he says is aimed at bringing pharmaceutical manufacturing back to the United States. The announcement gives companies a two-year window before significantly higher import duties come into effect.
Zero tariffs to continue before phased duty hike
Under the new policy, imported generic medicines will continue to attract zero tariffs from August 1, 2026, for the next two years. After the transition period ends, imports will face a 100% tariff for one year, followed by a 200% duty thereafter. Announcing the decision on his Truth Social platform, Trump said, “Effective August 1st, 2026, all Generic Drugs being brought into the United States will continue to have a TARIFF of ZERO PERCENT for a two-year period of time, after which the TARIFF will be raised to 100% for a one-year period of time, and 200% thereafter,” outlining the timeline for the new import policy.
Trump says policy will boost US manufacturing
Explaining the objective behind the decision, Trump said the tariff structure has been designed to encourage pharmaceutical companies to establish manufacturing plants in the United States instead of depending on overseas production. He said, “This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them. The objective of this Policy is to protect the people of the United States,” indicating that companies would have sufficient time to shift production before the higher duties take effect.
Existing policy for branded medicines remains unchanged
Trump also clarified that the latest tariff proposal applies only to generic medicines and does not alter the current framework governing patented and branded pharmaceutical products. He said, “The Policy on Patented, Branded, or Innovative Drugs, which has been so successful, will remain as is. Pharmaceutical Facilities are being built, at a level never seen before, all over the United States of America,” while claiming that domestic investment in pharmaceutical manufacturing has already accelerated.
Generic medicines play a key role in US healthcare
Generic medicines account for more than 90% of prescriptions dispensed in the United States, according to the US Food and Drug Administration (FDA), making them a critical component of the country’s healthcare system due to their affordability and widespread availability. Any significant change in import duties is expected to have implications for global pharmaceutical exporters supplying the American market.
Part of broader economic strategy
The announcement aligns with Trump’s broader economic agenda of increasing domestic manufacturing and reducing dependence on imported products. His administration has previously introduced policies encouraging pharmaceutical companies to manufacture within the United States while linking tariff exemptions and pricing arrangements to domestic investment. The latest proposal further strengthens that strategy by offering a transition period before imposing substantially higher tariffs on imported generic medicines.
Q1. What is Donald Trump’s new tariff policy on generic medicines?
The policy keeps tariffs on imported generic medicines at 0% for two years from August 1, 2026, before increasing them to 100% for one year and 200% thereafter.
Q2. Why is Trump introducing these tariffs?
The policy aims to encourage pharmaceutical companies to relocate manufacturing operations to the United States and reduce dependence on imported generic medicines.
Q3. Will branded medicines also face the new tariffs?
No. Trump said the existing policy for patented, branded and innovative medicines will remain unchanged.
Q4. Why are generic medicines important in the US?
Generic medicines account for over 90% of prescriptions filled in the United States and are widely used because they are more affordable than branded alternatives.
